Big Pharma Split Corp. Class A
TTSX:PRM15.01
CAD
-0.23
(-1.51%)
ISIN
CA08934P1080
CUSIP
08934P108
Return %
Stock
S&P 500
1Y
23.95
14.20
3Y
4.24
81.12
5Y
11.19
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Semi-annual Revenue
CAD
•
in mil. unless spec.Semi-annual Earnings Per Share
CAD
•
in mil. unless spec.Semi-annual Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Louis Michael Kovacs
- Sector
- Miscellaneous
- Industry
- Investment trusts
- Address
- 610 Chartwell Road Oakville ON Canada L6j 4A5
- IPO Date
- Nov 24, 2017
- Website
- harvestportfolios.com
- Similar Companies
- Business
- Big Pharma Split Corp. operates as a closed-end equity investment fund managed by Harvest Portfolios Group Inc., primarily engaged in investing in equity securities of major pharmaceutical and biotechnology companies. Its portfolio is initially equally weighted across ten issuers in the pharmaceutical and biotechnology sectors, including leading U.S.-based companies such as Eli Lilly and Company, Johnson & Johnson, AstraZeneca, Merck & Co., GSK, AbbVie, Amgen, Bristol-Myers Squibb, Pfizer, and Sanofi. The fund seeks to provide monthly and quarterly cash distributions to shareholders through its common and preferred shares listed on the Toronto Stock Exchange since its inception on November 24, 2017. Big Pharma Split Corp. mainly focuses on providing investors with exposure to large-cap pharmaceutical equities, aiming to deliver income and potential capital appreciation, with portfolio management centered in Canada and holdings primarily in the United States. The fund's core products and services consist of managing an equity portfolio of shares in the top pharmaceutical and biotechnology companies, offering structured income-generating investment products through its common share (PRM) and preferred share (PRM.PR.A) classes. It offers a monthly distribution on common shares and quarterly on preferred shares, with a total asset under management of approximately CAD 27.3 million as of late 2025. Recent operational updates include the ongoing distribution of monthly and quarterly cash payments to shareholders, maintaining the portfolio's focus on large pharmaceutical companies as of the latest data in late 2025. The latest major business activities emphasize sustaining income distributions and portfolio rebalancing rather than new product launches or strategic shifts, reflecting its passive investment strategy in established pharmaceutical equities. Big Pharma Split Corp. is part of the broader Harvest Portfolios Group Inc. ecosystem, which manages various investment funds focusing on income and growth for Canadian investors. Founded in 2009 and headquartered in Oakville, Ontario, Harvest Portfolios Group provides a range of exchange-traded funds, mutual funds, and structured products. Big Pharma Split Corp. operates within the pharmaceuticals and biotechnology sectors in North America, targeting investors seeking dividend income and exposure to the pharmaceutical industry's stable and large-cap companies. There have been no recent acquisitions or significant changes to the fund's investment mandate or structure reported in the past one to two years, with the focus remaining on income generation from a concentrated portfolio of major pharmaceutical equities.